The full approval of Eisai and Biogen’s Leqembi clears the way for broader Medicare coverage of the treatment, which has been limited.| Alzheimer's News Today
Steve Bryson is a science writer for Alzheimer's News Today with a PhD in biochemistry. He covers the latest news and information on a variety of Alzheimer's topics.| Alzheimer's News Today
Under-the-skin injections worked better in trial than the approved Leqembi formulation in clearing harmful amyloid plaques in Alzheimer's.| Alzheimer's News Today
Just-released full data from the Phase 3 Clarity AD trial show lecanemab can significantly slow dementia in early-onset Alzheimer’s patients.| Alzheimer's News Today
The immunotherapy Leqembi, formerly BAN2401, is now FDA-approved for slowing cognitive decline in patients with Alzheimer's disease.| Alzheimer's News Today
Category archive page for News.| Alzheimer's News Today
Eisai is seeking FDA approval of a monthly maintenance IV regimen of Leqembi for people with early Alzheimer’s disease.| Alzheimer's News Today
Learn more about Alzheimer's disease, the most common cause of dementia and an irreversible, progressive neurological disorder.| Alzheimer's News Today
